

Update on the role of genetics in the onset of age-related macular degeneration

Peter James Francis
Michael L Klein

Macular Degeneration Center, Casey
Eye Institute, Oregon Health and
Science University, Portland, OR, USA

Abstract: Age-related macular degeneration (AMD), akin to other common age-related diseases, has a complex pathogenesis and arises from the interplay of genes, environmental factors, and personal characteristics. The past decade has seen very significant strides towards identification of those precise genetic variants associated with disease. That genes encoding proteins of the (alternative) complement pathway (*CFH*, *C2*, *CFB*, *C3*, *CFI*) are major players in etiology came as a surprise to many but has already lead to the development of therapies entering human clinical trials. Other genes replicated in many populations *ARMS2*, *APOE*, variants near *TIMP3*, and genes involved in lipid metabolism have also been implicated in disease pathogenesis. The genes discovered to date can be estimated to account for approximately 50% of the genetic variance of AMD and have been discovered by candidate gene approaches, pathway analysis, and latterly genome-wide association studies. Next generation sequencing modalities and meta-analysis techniques are being employed with the aim of identifying the remaining rarer but, perhaps, individually more significant sequence variations, linked to disease status. Complementary studies have also begun to utilize this genetic information to develop clinically useful algorithms to predict AMD risk and evaluate pharmacogenetics. In this article, contemporary commentary is provided on rapidly progressing efforts to elucidate the genetic pathogenesis of AMD as the field stands at the end of the first decade of the 21st century.

Keywords: genes, complex disease, susceptibility, AMD

Introduction

Individuals who develop age-related macular degeneration (AMD) lose central vision due to involvement of the macula, the central region of the retina specialized to distinguish fine detail, thus permitting activities such as reading, recognizing faces, and driving. Although several retinal layers are affected, vision is primarily lost when photoreceptors die. The term age-related maculopathy (ARM) describes the spectrum of age-related macular changes, from the early presence of a few small drusen (sub-retinal lipid and protein-containing deposits which are the hallmark of the condition) to the most advanced stages with severe anatomic changes accompanied by vision loss.^{1,2} Patients with larger and more numerous drusen, often with advanced or visually significant ARM, are referred to as having AMD.³ Two advanced forms of the disease are recognized: “dry” or atrophic AMD (geographic atrophy), in which atrophy of the retinal pigment epithelium (RPE) results in untreatable progressive visual loss; and “wet” or neovascular AMD, characterized by the intraretinal invasion of vessels from the choroid, which usually bleed and form dense macular scars.

Correspondence: Peter James Francis
Macular Degeneration Center,
Casey Eye Institute, Oregon Health and
Science University, 3375 SW Terwilliger
Bldv, Portland, OR 97239, USA
Tel +1 503 418 1627
Fax +1 503 494 7233
Email francisp@ohsu.edu

One-and-three-quarter million individuals in the United States have the advanced, visually disabling form of AMD. More than seven million additional individuals have earlier retinal changes, placing them at high risk of developing advanced AMD. In those older than 75 years, the prevalence of advanced disease is approximately 8%, and 30% will develop degenerative macular changes consistent with earlier forms of the disease.⁴ With the expected increase in the number of older individuals in the population, it is predicted that the prevalence of AMD will increase by more than 50% by the year 2020, substantially increasing the health burden from AMD.⁵

Neovascular AMD is the cause of most cases of legal blindness. Symptoms may progress rapidly over days to weeks, with the major complaints being reduced acuity and distortion. Clinical examination typically reveals the presence of subretinal fluid and hemorrhage. Intra- and subretinal edema and hemorrhage may also be accompaniments.^{6,7} As the disease progresses, retinal gliosis may develop, together with permanent visual loss. Neovascularization is best delineated on fluorescein angiography where several patterns are well recognized. The mainstay of clinical evaluation has recently become optical coherence tomography, which has enabled very sensitive detection of retinal and subretinal fluid and therefore guides the need for treatment with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.⁸ Geographic atrophy is characterized by enlarging area(s) of outer retinal atrophy (retinal pigment epithelium and photoreceptors) in the macular region that typically and inexorably expands to affect the fovea.

Extensive epidemiologic and genetic analyses have lead to the conclusion that AMD, like many other chronic age-related diseases, results from the interplay of multiple environmental and genetic factors, which in combination account for development of the phenotype. The condition is strongly age-related, and tobacco smoking is the most consistent and modifiable significant risk factor.^{9–11} Other environmental risk factors that have been reported include cardiovascular disease,^{12–14} hypertension,^{15,16} high body mass index,¹⁷ and low education level.¹⁸

Genetic susceptibility and AMD

It is now beyond question that genes play a significant etiological role in AMD.^{19,20} Studies to identify genetic AMD-susceptibility variants have utilized all available techniques such as genome-wide linkage approaches (twins, sib pairs, and families)^{21–27} and case-control association studies. A table of replicated AMD-susceptibility genes is shown in Table 1. For the most part, studies have been limited to the

Table 1 Replicated AMD-susceptibility genes

| Gene | Effect of minor allele on odds ratio of having AMD |
|-------------------|--|
| <i>CFH</i> | ↑ |
| <i>ARMS2</i> | ↑ |
| <i>C2</i> | ↓ |
| <i>C3</i> | ↑ |
| <i>CFI</i> | ↑ |
| <i>ABCA1</i> | ↑ |
| <i>LIPC</i> | ↑ |
| <i>CETP</i> | ↑ |
| <i>LPL</i> | ↑ |
| <i>Near TIMP3</i> | ↑ |

Abbreviation: AMD, age-related macular degeneration.

study of the phenotypic extremes; that is, advanced cases or those with no signs of the condition, and case-control populations of extreme phenotypes. This is because it is reasonably achievable to ascertain these phenotypes. There are a few clinical caveats. Firstly, while it is straightforward to identify advanced AMD, often atrophy and neovascular disease coexist either in the same eye or in the fellow eye, and how to group these individuals is potentially problematic. Furthermore, it is less routine to rule out the presence of neovascular AMD in an eye with apparent geographic atrophy. Since the presence of small drusen is almost universal in older individuals, it is somewhat arbitrary how few need to be present for an eye to remain a control.

Intermediate stages of AMD are more difficult to phenotype and require quantification of such endophenotypes such as drusen (size, number, distribution, area) and macular pigment epithelial changes (hypo-/hyper-, area) which are challenging and less well appreciated from the perspective of disease staging. As such, very limited information is currently available regarding the genetic architecture of intermediate AMD.

Early studies

Early studies concentrated on genome-wide linkage and familial association analyses (twins, sib pairs, and families).^{21–23} The first genetic locus for AMD was localized in a single large pedigree to chromosome 1q.²⁸ Later, a co-segregating variant in *HMCN-1* (*hemicentin-1*) was identified.²⁹ *HMCN-1* lies in close proximity to the *CFH* (*complement factor H*) gene, discussed below. Meta-analysis of a number of linkage studies²⁴ consistently identified this same locus and several other genomic regions which were later shown to harbor specific genetic variants. Others remain the subject of further investigation.^{25–27}

Complement genes

The first well established specific genetic variant to be associated with advanced AMD was the single nucleotide polymorphism (SNP) rs1061170 (T1277C; Y402H) in the *CFH* gene.^{30–32} This finding has been replicated by numerous studies.³³ Additional analyses of the *RCA* locus on chromosome 1q in which the gene resides have concluded that haplotypes encompassing both *CFH*^{34,35} and neighboring genes,³⁶ acting independently or in concert with the Y402H change, confer increased risk of drusen formation and advanced AMD.^{33,37} Subsequent analyses of the complement pathway identified SNPs in other complement components: complement factors *C2*, *CFB*,^{38,39} *C3*,^{40,41} and *CFI*.⁴² *CFH* is a regulator of complement activation, dysfunction of which has been linked to retinal pathology.⁴³

The challenges of 10q26

Early genome-wide linkage studies consistently identified an AMD susceptibility locus on chromosome 10q26.^{24,25} A combination of genotyping and direct sequencing of this region initially identified two SNPs, 6 kb apart, in high linkage disequilibrium in many Caucasian populations,⁴⁴ that are strongly associated with advanced AMD, as follows.

- The rs10490924 (A69S) variant lies within the putative gene, *LOC387715*, now named *ARMS2* (*age-related maculopathy susceptibility 2*).^{45,46} *ARMS2* has no known function, and the predicted protein shows little homology with other proteins. *ARMS2* is only present in higher primates, and mRNA transcripts can be detected in the retina. Whether the protein is translated is still debated. Immunohistochemical analyses have provided conflicting evidence localizing protein within the mitochondrion⁴⁷ in the inner segment of the photoreceptor,⁴⁸ the cytoplasm, among other locations. Most recently, an indel in *ARMS2* has been reported that appears to affect translation of the protein and has been postulated to be the functional variant at the 10q26 locus.⁴⁸
- The rs11200638 SNP resides in the promoter of the gene, *HTRA1*,^{49,50} a serine protease found in the retina (among other tissues). Preliminary, functional analyses suggest that the polymorphism at this position alters expression levels of the gene.⁴⁹

The era of genome-wide SNP-association studies (GWAS)

Modern advances in genotyping technology have facilitated the high-throughput analysis of hundreds of thousands of single-nucleotide polymorphisms on a single chip. In 2010, a consortium of researchers published the results

of two independent GWASs with subsequent replication of positive findings. These studies identified several new genes associated with advanced AMD status.^{51,52} Of interest, this study implicated genes associated with lipid metabolism, specifically the HDL pathway, *ABCA1*, *LIPC*, *CETP*, and *LPL*. Other replicated findings included significantly associated SNPs near the gene encoding *TIMP3* (tissue inhibitor of metalloproteinase 3), which is involved in remodeling of the extracellular matrix in the retina.

Other genes

Associations in the genes APOE (apolipoprotein E),^{53–55} ABCA4 (ATP-binding cassette A4),^{56,57} CX3CR1 (chemokine 3 receptor 1),^{58,59} PON1,⁶⁰ TLR4 (toll-like receptor 4),⁶¹ ERCC6,⁶² ELOVL4,^{63,64} VLDLR (very low density lipoprotein receptor),⁶⁵ fibulin-5,⁶⁶ hemicentin-1,²⁹ TLR3 (toll-like receptor 3),⁶⁷ C1q (complement factor C1q),⁶⁸ VEGF (vascular endothelial growth factor),^{65,69,70} SERPING1,^{71,72} and LRP6⁶⁵ have been reported in single populations.

Pharmacogenetics in AMD

The identification of common genetic variants that contribute significantly to the etiology of AMD has garnered interest in evaluating whether these same SNPs and other candidate genes may play a role in treatment response (pharmacogenetics).

Pharmacogenetics attempts to define the genetic variants that determine variable response to medication. The ultimate goal is to identify those who respond best and avoid adverse reactions. Garrod first recognized a familial or genetic tendency to variability in drug response⁷³ and hypothesized that drugs were metabolized by specific pathways of genes in which defects would result in differences in drug concentrations and therefore drug effect. A large number of studies have now defined pharmacogenetic interactions in many biomedical fields. These include therapies for neurological and psychiatric disorders,^{74–76} asthma,⁷⁷ cardiovascular disease,⁷⁸ and cancer.^{79,80}

Initial studies in AMD have focused on three different treatments: Age-Related Eye Disease Study (AREDS) supplementation, photodynamic therapy (PDT), and anti-VEGF therapy. In all instances, studies to date have been limited to retrospective analyses.

Anti-VEGF agents

In one retrospective study, 86 patients being treated with bevacizumab (Avastin™) alone were evaluated for associations between treatment response and common

polymorphisms in the genes *CFH* and *ARMS2*. Patients homozygous for both *CFH* risk alleles (CC) had worse visual outcomes than those with the *CFH* TC and TT genotypes.⁸¹ In a similar retrospective analysis, but involving 156 patients who were receiving ranibizumab, the same authors were able to replicate this finding.⁸² These studies were well conducted; however, the associations do not necessarily imply causality and there may have been additional confounders.

AREDS supplements

The AREDS was an 11-center National Institutes of Health-funded study initiated in 1992 with 4757 participants. It included an 8-year randomized control trial which established that a combination of zinc and antioxidants (beta-carotene, vitamin C, and vitamin E) produced a 25% reduction in development of advanced AMD and a 19% reduction in severe vision loss in individuals determined to be at high risk of developing the advanced forms of the disease.⁶ Conversely, 22% of participants receiving antioxidants and zinc had a 15-letter decrease in visual acuity despite treatment. Use of these oral supplements is now current standard of practice in the United States. Indeed, they remain the only therapy for early, intermediate,⁶ and dry AMD.⁸³

A recent evaluation of the AREDS cohort found evidence of an interaction between the *CFH* genotype and treatment with antioxidants plus zinc when compared with placebo. This interaction appears to have arisen because supplementation was associated with a greater reduction in AMD progression (68%) in those with the low risk TT genotype compared with those with the high risk CC genotype (11%).

These results may imply that the strong genetic predisposition to AMD conferred by the CC genotype limits the benefits available from zinc and antioxidants (beta-carotene, vitamin C, and vitamin E).⁸⁴ In this pharmacogenetics study, the authors evaluated whether known AMD-susceptibility genotypes in those who at entry into the study had early to intermediate AMD and progressed to advanced disease were associated with treatment assignment. Previously, these same genes had been reported to be independently associated with progression to advanced AMD.^{85,86} There is good biological plausibility to support a possible role for *CFH*. Evidence supports the assertion that *CFH* protein dysfunction results in excessive inflammation and tissue damage of the type involved in the pathogenesis of AMD.^{9,20} Inflammation is known to intensify oxidative stress,²¹ and since AREDS supplements are thought to have an antioxidant effect,^{22–25} it seems reasonable to assume that *CFH* polymorphisms could play a role in treatment response.^{13,14}

PDT

PDT was until recently the most widely used therapy for neovascular AMD and still retains a role for individuals in whom anti-VEGF agents are contraindicated.⁸⁷ PDT to the macula induces thrombosis of neovascular vessels (choroidal neovascularization) which have been photosensitized by the administration of verteporfin.⁸⁸ Efficacy was originally established in a series of randomized control trials including the TAP (Treatment of Age-Related Macular Degeneration with Photodynamic Therapy), VIP (Visudyne in Photodynamic Therapy), and Visudyne in Minimally Classic Choroidal Neovascularization studies.⁸⁷ Considerable variability in response is observed with PDT and may vary by ethnicity.⁸⁹ In an attempt to identify whether genetic influences are involved, a set of variants in genes associated with thrombosis were retrospectively evaluated in two studies (84 and 90 subjects). Patients were divided into those that were PDT “responders” and those that were “nonresponders” (3-month follow-up). Patients were genotyped for factor V G1691A, prothrombin G20210A, factor XIII-A G185T, methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, and methionine synthase reductase A66G. “Nonresponse” was more frequent in those with the hyperfibrinolytic G185T gene polymorphism of factor XIII-A, and response was associated with those with the thrombophilic factor V 1691A and prothrombin 20210A alleles.^{89–91}

As this article is being written, several other prospective pharmacogenetic studies are nearing completion. Cumulatively, these should provide further significant insights into those variants involved with treatment response in AMD.

Predicting the risk of developing advanced AMD

The idea of employing a risk assessment algorithm to identify individuals at risk of developing AMD is attractive. The fact that drusen, the hallmark of the condition, appear prior to the development of vision loss offers an unusually useful clinical feature that might be combined with genetic and environmental risk factors to give an accurate risk assessment. Several such models have been proposed. Seddon et al described a model derived from the AREDS study population that included all these factors using the AREDS clinical AMD grading scale.⁹² In the model, points are assigned for the risk factors in their model to determine an individual's risk score. Zanke et al described a model that gives a lifetime risk estimate based on genetics and environmental factors,⁹³ and recently Chen et al proposed a model that examined risk of bilateral involvement.⁹⁴ There is no conclusive evidence that

genetic variants assist in predicting progression of disease once advanced AMD is established. One study found no association of progression of geographic atrophy with variants in the *CFH*, *C3*, and *ARMS2* genes.⁹⁵ A second study found no association of progression with variants in *CFH*, *C2*, *C3*, and *CFI*, but did note a nominal association with *ARMS2*.⁹⁶

Concluding remarks

AMD is a major health burden and one that is rapidly growing as the population of the Western world ages, en masse. Although the introduction of anti-VEGF agents has revolutionized outcomes for those with the less common neovascular form of AMD, there is limitation to the effectiveness of these regimens. There is currently neither effective treatment for geographic atrophy nor for earlier stages of disease. Dissecting the genetic etiology of the condition holds substantial promise for the identification of new avenues for therapeutic development. It is likely that conventional genome-wide and candidate gene approaches may have reached their limit to resolve new variants. Genome-wide strategies are not themselves redundant but will be superseded by next-generation technology such as whole Exmore and full genome sequencing.⁹⁷ Furthermore, the analysis of individuals with intermediate AMD phenotypes and the use of extended pedigrees with carefully quantified endophenotypes offer the opportunity to investigate less common, rarer, and private mutations, otherwise largely unidentifiable using case-control populations.

Acknowledgments

The authors are supported by grants from the Casey Eye Institute Macular Degeneration Fund, Research to Prevent Blindness, New York, NY (unrestricted grant to Casey Eye Institute and a Career Development Award), and the Foundation Fighting Blindness (USA). The authors would like to thank Nova Publishers for allowing re-printing in part of the article published in their book: 'Macular Degeneration: Causes, Diagnosis and Treatment'; Editor/Author: Eddie J. Campbell and Leslie M. McMann; ISBN: 978-1-61209-345-1.'

Disclosure

The authors report no conflicts of interest in this work.

References

- Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. *Surv Ophthalmol*. 1995;39(5):367–374.
- Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. *Ophthalmology*. 2007;114(6):1157–1163.
- Klein ML, Francis PJ. Genetics of age-related macular degeneration. *Ophthalmol Clin North Am*. 2003;16(4):567–574.
- Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology*. 1992;99(6):933–943.
- Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol*. 2004;122(4):564–572.
- A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol*. 2001;119(10):1417–1436.
- Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. *Clin Trials*. 2004;1(1):91–107.
- Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab. Phase III clinical trial results. *Ophthalmol Clin North Am*. 2006;19(3):361–372.
- Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. *Eye*. 2005;19(9):935–944.
- Evans JR, Fletcher AE, Wormald RP. 28,000 cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. *Br J Ophthalmol*. 2005;89(5):550–553.
- Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report no. 19. *Ophthalmology*. 2005;112(4):533–539.
- Klein R, Deng Y, Klein BE, et al. Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study. *Am J Ophthalmol*. 2007;143(3):473–483.
- Klein R, Klein BE, Knudtson MD, et al. Subclinical atherosclerotic cardiovascular disease and early age-related macular degeneration in a multiracial cohort: the Multiethnic Study of Atherosclerosis. *Arch Ophthalmol*. 2007;125(4):534–543.
- Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. *Ophthalmology*. 2007;114(4):732–737.
- Guymer RH, Chong EW. Modifiable risk factors for age-related macular degeneration. *Med J Aust*. 2006;184(9):455–458.
- Klein R, Klein BE, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. *Ophthalmology*. 2006;113(3):373–380.
- Seddon JM, George S, Rosner B, Klein ML. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. *Hum Hered*. 2006; 61(3):157–165.
- Francis PJ, George S, Schultz DW, et al. The LOC387715 gene, smoking, body mass index, environmental associations with advanced age-related macular degeneration. *Hum Hered*. 2007;63(3–4):212–218.
- Klein ML, Mauldin WM, Stoumbos VD. Heredity and age-related macular degeneration. Observations in monozygotic twins. *Arch Ophthalmol*. 1994;112(7):932–937.
- Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. *Am J Ophthalmol*. 1997;123(2):199–206.
- Majewski J, Schultz DW, Weleber RG, et al. Age-related macular degeneration – a genome scan in extended families. *Am J Hum Genet*. 2003;73(3):540–550.
- Kenealy SJ, Schmidt S, Agarwal A, et al. Linkage analysis for age-related macular degeneration supports a gene on chromosome 10q26. *Mol Vis*. 2004;10:57–61.
- Santangelo SL, Yen CH, Haddad S, Fagerness J, Huang C, Seddon JM. A discordant sib-pair linkage analysis of age-related macular degeneration. *Ophthalmic Genet*. 2005;26(2):61–67.
- Fisher SA, Abecasis GR, Yashar BM, et al. Meta-analysis of genome scans of age-related macular degeneration. *Hum Mol Genet*. Aug 1 2005;14(15):2257–2264.

25. Barral S, Francis PJ, Schultz DW, et al. Expanded genome scan in extended families with age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2006;47(12):5453–5459.
26. Schmidt S, Scott WK, Postel EA, et al. Ordered subset linkage analysis supports a susceptibility locus for age-related macular degeneration on chromosome 16p12. *BMC Genet*. 2004 Jul 6;5:18.
27. Schultz DW, Weleber RG, Lawrence G, et al. HEMICENTIN-1 (FIBULIN-6) and the 1q31 AMD locus in the context of complex disease: review and perspective. *Ophthalmic Genet*. 2005;26(2):101–105.
28. Klein ML, Schultz DW, Edwards A, et al. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. *Arch Ophthalmol*. 1998;116(8):1082–1088.
29. Schultz DW, Klein ML, Humpert AJ, et al. Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. *Hum Mol Genet*. 2003;12(24):3315–3323.
30. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. *Science*. 2005;308(5720):385–389.
31. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. *Science*. 2005;308(5720):419–421.
32. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. *Science*. 2005;308(5720):421–424.
33. Francis PJ, Schultz DW, Hamon S, Ott J, Weleber RG, Klein ML. Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration. *PLoS ONE*. 2007;2(11):e1197.
34. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2005;102(20):7227–7232.
35. Hageman GS, Hancox LS, Taiber AJ, et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. *Ann Med*. 2006;38(8):592–604.
36. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. *Nat Genet*. 2006;38(10):1173–1177.
37. Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. *PLoS Med*. 2006;3(1):e5.
38. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. *Nat Genet*. 2006;38(4):458–462.
39. Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. *Hum Mol Genet*. 2007;16(16):1986–1992.
40. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. *N Engl J Med*. 2007;357(6):553–561.
41. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. *Nat Gen*. 2007;39(10):1200–1201.
42. Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near complement factor I is associated with risk of advanced AMD. *Eur J Hum Genet*. 2009;17(1):100–104.
43. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. *Prog Retin Eye Res*. 2001;20(6):705–732.
44. Francis PJ, Zhang H, Dewan A, Hoh J, Klein ML. Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population. *Mol Vis*. 2008;14:1395–1400.
45. Rivera A, Fisher SA, Fritsche LG, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. *Hum Mol Genet*. 2005;14(21):3227–3236.
46. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. *Am J Hum Genet*. 2005;77(3):389–407.
47. Kanda A, Chen W, Othman M, et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2007;104(41):16227–16232.
48. Fritsche LG, Loenhardt T, Janssen A, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. *Nat Genet*. 2008;40(7):892–896.
49. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. *Science*. 2006;314(5801):989–992.
50. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. *Science*. 2006;314(5801):992–993.
51. Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2010;107(16):7401–7406.
52. Neale BM, Fagerness J, Reynolds R, et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). *Proc Natl Acad Sci U S A*. 2010;107(16):7395–7400.
53. Baird PN, Guida E, Chu DT, Vu HT, Guymer RH. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2004;45(5):1311–1315.
54. Baird PN, Richardson AJ, Robman LD, et al. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). *Hum Mut*. 2006;27(4):337–342.
55. Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. *Am J Hum Genet*. 1998;63(1):200–206.
56. Allikmets R. Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium. *Am J Hum Genet*. 2000;67(2):487–491.
57. Allikmets R, Shroyer NF, Singh N, et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. *Science*. 1997;277(5333):1805–1807.
58. Combadiere C, Feumi C, Raoul W, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. *J Clin Invest*. 2007;117(10):2920–2928.
59. Tuo J, Smith BC, Bojanowski CM, et al. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. *Faseb J*. 2004;18(11):1297–1299.
60. Baird PN, Chu D, Guida E, Vu HT, Guymer R. Association of the M55 L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. *Am J Ophthalmol*. 2004;138(4):665–666.
61. Zarepari S, Buraczynska M, Branham KE, et al. Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration. *Hum Mol Genet*. 2005;14(11):1449–1455.
62. Tuo J, Ning B, Bojanowski CM, et al. Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition. *Proc Natl Acad Sci U S A*. 2006;103(24):9256–9261.
63. Conley YP, Jakobsdottir J, Mah T, et al. CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses. *Hum Mol Genet*. 2006;15(21):3206–3218.
64. Conley YP, Thalamuthu A, Jakobsdottir J, et al. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. *Hum Mol Genet*. 2005;14(14):1991–2002.

65. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. *Invest Ophthalmol Vis Sci.* 2006;47(1):329–335.
66. Stone EM, Braun TA, Russell SR, et al. Missense variations in the fibulin 5 gene and age-related macular degeneration. *N Engl J Med.* 2004;351(4):346–353.
67. Yang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. *N Engl J Med.* 2008;359(14):1456–1463.
68. Ennis S, Jomary C, Mullins R, et al. Association between the SERP-ING1 gene and age-related macular degeneration: a two-stage case-control study. *Lancet.* 2008;372(9652):1828–1834.
69. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. *Hum Mol Genet.* 2006;15(19):2955–2961.
70. Francis PJ, Hamon SC, Ott J, Weleber RG, Klein ML. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. *J Med Genet.* 2009;46(5):300–307.
71. Ennis S, Jomary C, Mullins R, et al. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. *Lancet.* 2008;372(9652):1828–1834.
72. Nakata I, Yamashiro K, Yamada R, et al. Association between the SERPING1 gene and age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese. *PLoS ONE.* 2011;6(4):e19108.
73. Motulsky AG, Harper PS, Bobrow M, Scriver C. *Pharmacogenetics.* New York: Oxford University Press; 1997.
74. Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. *Am J Pharmacogenomics.* 2001;1(1):3–10.
75. Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. *Dialogues Clin Neurosci.* 2006;8(1):85–94.
76. Depondt C, Shorvon SD. Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications. *Pharmacogenomics.* 2006;7(5):731–745.
77. Weiss ST, Litonjua AA, Lange C, et al. Overview of the pharmacogenetics of asthma treatment. *Pharmacogenomics J.* 2006;6(5):311–326.
78. Manunta P, Bianchi G. Pharmacogenomics and pharmacogenetics of hypertension: update and perspectives – the adducin paradigm. *J Am Soc Nephrol.* 2006;17(4 Suppl 2):S30–S35.
79. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. *J Clin Oncol.* 2006;24(26):4236–4244.
80. Barry EL, Baron JA, Bhat S, et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. *J Natl Cancer Inst.* 2006;98(20):1494–1500.
81. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. *Ophthalmology.* 2007;114(12):2168–2173.
82. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. *Br J Ophthalmol.* 2009;93(5):610–613.
83. Sunness JS, Gonzalez-Baron J, Applegate CA, et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration. *Ophthalmology.* 1999;106(9):1768–1779.
84. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. *Ophthalmology.* 2008;115(6):1019–1025.
85. Francis PJ, Hamon S, Ott J, Weleber RG, Klein M. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age-related macular degeneration associated with visual loss. *J Med Genet.* 2009;46(5):300–307.
86. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFHY402H and LOC387715 A69S with progression of age-related macular degeneration. *JAMA.* 2007;297(16):1793–1800.
87. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment – TAP and VIP report No. 2. *Arch Ophthalmol.* 2003;121(9):1253–1268.
88. Koh AH, Ang CL. Age-related macular degeneration: what's new. *Ann Acad Med Singapore.* 2002;31(3):399–404.
89. Parmeggiani F, Costagliola C, Gemmati D, et al. Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration. *Invest Ophthalmol Vis Sci.* 2008;49(7):3100–3106.
90. Parmeggiani F, Costagliola C, Gemmati D, et al. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. *Pharmacogenet Genomics.* 2007;17(12):1039–1046.
91. Parmeggiani F, Gemmati D, Costagliola C, Sebastiani A, Incorvaia C. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. *Pharmacogenomics.* 2009;10(1):81–95.
92. Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. *Invest Ophthalmol Vis Sci.* 2009;50(5):2044–2053.
93. Zanke B, Hawken S, Carter R, Chow D. A genetic approach to stratification of risk for age-related macular degeneration. *Can J Ophthalmol.* 2010;45(1):22–27.
94. Chen Y, Zeng J, Zhao C, et al. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. *Arch Ophthalmol.* 2011;129(3):344–351.
95. Scholl HP, Fleckenstein M, Fritsche LG, et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. *PLoS ONE.* 2009;4(10):e7418.
96. Klein ML, Ferris FL 3rd, Francis PJ, et al. Progression of geographic atrophy and genotype in age-related macular degeneration. *Ophthalmology.* 2010;117(8):1554–1559, 1559.e1551.
97. Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. *Nature.* 2010;466(7307):714–719.

Clinical Ophthalmology

Publish your work in this journal

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: <http://www.dovepress.com/clinical-ophthalmology-journal>

Dovepress

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.